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Purpose: Small airway changes and dysfunction contribute importantly to airway obstruction
in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled
corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung
Disease (GOLD) grades 2–4. This retrospective matched cohort analysis compared effectiveness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS
(fluticasone) in primary care patients with COPD.
Patients and methods: Smokers and ex-smokers with COPD $40 years old initiating or
stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demographic characteristics, index prescription year, concomitant therapies, and disease severity
during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD
exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids,
or antibiotics for lower respiratory tract infection.
Results: Mean patient age was 67 years, 57%–60% being male. For both initiation (n=334:334)
and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine
beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment
stability (no exacerbation or treatment change) were significantly greater for patients initiating
extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence
interval, 1.32–4.73). Median ICS dose exposure during 2 outcome years was significantly lower
(P,0.001) for extrafine beclomethasone than fluticasone cohorts (315 µg/day versus 436 µg/day
for initiation, 438 µg/day versus 534 µg/day for step-up patients).
Conclusion: We observed that small-particle ICS at significantly lower doses had comparable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation
of small-particle ICS was associated with better odds of treatment stability during 2-years’
follow-up.
Keywords: COPD exacerbation, extrafine particle, matched cohort analysis, real life,
small airways

Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by chronic inflammation in airway walls and lung tissue, dysfunctional
repair and defense mechanisms, excessive mucus production, and changes in the
small peripheral airways.1,2 These changes include thickening of small airway walls,
loss of elasticity, airway obstruction, and accompanying emphysema.3–5 A recent
study found that loss of functional small airways may precede the development of
emphysema in COPD and thus the small airways may constitute an appropriate
target for treatment.6,7
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Consensus practice guidelines for COPD recommend the
use of inhaled corticosteroids (ICS) together with inhaled
long-acting bronchodilators for patients at high risk of
exacerbations, ie, with either forced expiratory volume in
1 second (FEV1) ,50% predicted or a history of repeated
exacerbations.1 In randomized controlled trials, ICS reduce
COPD exacerbations but are associated with a slight increase
in risk of pneumonia.1,8–10 In clinical practice, different from
current guideline recommendations, ICS monotherapy, usually with larger-particle ICS, is still being used for treatment
of COPD.11–13
Because COPD starts in the small airways, a pharmacological approach targeting the small airways with smallparticle ICS might be beneficial. It may, however, be difficult
to capture benefits related to small particle size in randomized
controlled trials, which usually recruit selected patients who
are cared for in a controlled context. Possible benefits might
be more evident in real-life patients, whose adherence is often
suboptimal and who may have COPD associated with other
diseases, for example, asthma-COPD overlap syndrome.1
The aim of this retrospective observational study was to
compare the effectiveness of a representative small-particle
ICS, extrafine beclomethasone,14–16 and a larger-particle-size
ICS, fluticasone, in a broad, real-life primary care population
of patients with COPD. Our hypothesis was that treatment
with small-particle ICS would be associated with improved
management and control of COPD, as compared with largerparticle ICS, because of better deposition throughout the
lungs and small airways.

Methods
Study design and patients
We performed retrospective matched cohort analyses using
de-identified patient information (1996–2010) from .450
primary care practices throughout the UK subscribing
to the General Practice Research Database (now in the
Clinical Practice Research Datalink)17 and approximately
300 practices subscribing to the Optimum Patient Care
Research Database.18 These two large electronic datasets,
described in detail elsewhere,17–21 are frequently used for
observational research. Patient characteristics were crossreferenced between the two datasets to avoid duplication
of individuals.
The two analyses examined patients prescribed their first
ICS treatment (initiation sample) and those prescribed an
increase in ICS dose (step-up sample) for COPD as either
extrafine beclomethasone (Qvar; Teva Pharmaceuticals,
Petach Tikva, Israel) or a commonly prescribed large-particle
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ICS, fluticasone (Flixotide; GlaxoSmithKline plc, London,
UK), by pressurized metered-dose inhaler. We included
male and female patients, $40 years old at the time of the
index study prescription (index date), who had: 1) a diagnostic code for COPD, and 2) two or more prescriptions for
COPD at different time points during the preceding year
(baseline). The baseline year COPD prescriptions could be
for any combination of the following: short-acting β2-agonist
(SABA), long-acting β 2-agonist (LABA), short-acting
muscarinic antagonist (SAMA), long-acting muscarinic
antagonist (LAMA), theophylline, and, for patients in the
step-up sample only, including an ICS. The diagnostic code
for COPD could be recorded at any time relative to the index
date ICS prescription. Eligible patients had to be registered
at the same general practice for at least 3 consecutive years,
including 1 year before (baseline year) and 2 years after the
index date (outcome period).
In practice COPD can be associated with or misdiagnosed
as asthma; therefore, eligible patients could also have had an
asthma diagnostic code but only if recorded for the first time
after 40 years of age. Patients were excluded if they had a coded
diagnosis pre-40-years for asthma or at any time for any chronic
respiratory disease other than COPD (exclusions listed in
Table S1). In addition, during the matching process (see below),
we excluded non-smokers and patients without spirometric
evidence of COPD (ie, without post-bronchodilator ratio of
FEV1 to forced vital capacity [FVC] [FEV1/FVC] ,0.7).

Outcome measures
Exacerbation rate and odds of COPD treatment success were
the two coprimary effectiveness measures. An exacerbation
was defined as the occurrence of any one of the following:
acute use of oral corticosteroids; unscheduled hospital admission or emergency department (ED) attendance for COPD
or respiratory-related event; lower respiratory tract infection
treated with antibiotics; or prescription for antibiotics with
a lower respiratory database code within a ±5 day window.
The absence of an exacerbation during the outcome period
defined COPD treatment success.
Secondary effectiveness measures included the time
to first exacerbation and treatment stability, defined as no
treatment change plus no exacerbation. Treatment change
was defined as an increase in ICS dose (of $50%) and/or
additional therapy (new since baseline year). Other outcomes
examined included the hospitalization rate for lower respiratory causes; mortality rate after the study; oral candidiasis
(coded diagnosis or therapy, namely, oral antifungal prescriptions); and two definitions of pneumonia: 1) unconfirmed
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cases with coded pneumonia diagnosis, and 2) pneumonia
confirmed by chest radiograph or hospitalization within
1 month of diagnosis code. All outcome measures were
derived from GP-provided Read codes in the electronic
databases.
All ICS doses were standardized to equivalency with
extrafine beclomethasone doses for the analyses, using a 1:1
ratio for extrafine beclomethasone and all fluticasone propionate formulations, and for both the latter a 1:2 dose ratio
relative to budesonide and larger-particle chlorofluorocarbonor hydrofluoroalkane-beclomethasone (Clenil Modulite;
Chiesi Ltd, Cheadle, UK). The mean daily ICS dose exposure
during baseline and outcome years was calculated as the
dispensed amount divided by 365 (baseline year) or 730
(outcome period).

Statistical analysis
We conducted a matched cohort analysis because the exploratory analysis found baseline differences between treatment
cohorts in both initiation and step-up samples. Unmatched
patients prescribed extrafine beclomethasone tended to be
slightly older and to have fewer baseline exacerbations than
those in the fluticasone cohorts. Most importantly, the index
date, which was later for extrafine beclomethasone cohorts,
was a strongly confounding variable because of trends over
time for earlier COPD diagnosis and treatment. Hospitalization
and mortality rates were significantly lower, and changes in
therapy significantly more likely, with later index dates.
Therefore, to eliminate these and minimize other baseline differences between treatment cohorts, we matched
in 1:1 ratio on the following criteria: sex; age (±5 years);
number of baseline year COPD exacerbations (0, 1, $2);
year of index prescription (±1 year for the initiation
sample and ±2 years for the step-up sample); and baseline
therapy (categorized as a) SABA/SAMA/SABA + SAMA;
b) LABA ± SABA ± SAMA; c) LAMA ± SABA ± SAMA;
d) LABA + LAMA ± SABA ± SAMA, and e) other). In
addition, for the step-up sample, we matched on mean daily
ICS dose exposure during baseline (categorized as 0–250,
251–500, and .500 µg/day). Finally, we matched on smoking status; confirmation of COPD ever via post-bronchodilator FEV1/FVC ratio ,0.7; and age at first asthma diagnosis
(,40 years old or $40 years old/no asthma diagnosis) as a
means of subsequently excluding – without losing matched
groupings – all non-smokers, patients without confirmed
COPD, and patients with asthma diagnosed before age 40.
Summary statistics were produced for all baseline and
outcome variables. For patients with available FEV1 values,
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the Global initiative for Obstructive Lung Disease (GOLD)
grade of severity of airflow limitation was determined.22 We
compared baseline characteristics and unadjusted outcome
variables for matched cohorts using conditional logistic
regression, categorizing heavily skewed data. The list of
potential confounders considered for the adjusted analyses included those differing between treatment cohorts at
baseline (P,0.10) and variables predictive (P,0.05) of
each outcome variable in multivariate analyses (Table S2).
Pearson and Spearman correlation coefficients were applied,
together with clinical interpretation, to eliminate variables
presenting collinearity issues in the regression modeling
of outcomes.
We used a conditional Poisson regression model to
calculate adjusted relative rates of exacerbations and of oral
candidiasis. The adjusted odds of achieving COPD treatment
success and treatment stability, and of having a treatment
change, were compared between cohorts using conditional
binary logistic regression models. A Cox proportional hazards
model, adjusted for baseline confounders, was used to examine the time to first exacerbation and post-study mortality.
(Patients had to be alive during the full 2 year outcome period
to be eligible for the study). To account for multiple comparisons, we controlled for false discovery rate if more than one
of the co-primary endpoints were significant.
The composite outcome measures and analyses were
prespecified according to standard operating procedures of
the research group.23 All analyses were carried out using
IBM SPSS Statistics version 19 (IBM Corporation, Armonk,
NY, USA), SAS version 9.2 (SAS Institute Inc., Cary, NC,
USA), and Microsoft Excel 2007 (Microsoft Corporation,
Redmond, WA, USA). We defined statistically significant
results as P,0.05.

Results
Patient identification in the datasets and subsequent matching
of 384 patients in each initiation cohort, and 189 patients in
each step-up cohort, are depicted in Figures S1 and S2.

Initiation sample
At baseline, the clinical characteristics of patients in extrafine
beclomethasone and fluticasone cohorts were similar
(Tables 1 and S3). Approximately 60% of patients were male,
and the mean age was 67 years. There were several significant
differences between cohorts (eg, in index prescription date,
cardiac disease diagnosis, and use of some drugs), but these
differences were small and not clinically meaningful. Most
patients were GOLD grade 2 or 3.22
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Table 1 Summary of key baseline patient characteristics by matched treatment cohorts and smoking status
Characteristic

Initiation sample

Step-up sample

Extrafine BDP
(n=334)

Fluticasone
(n=334)

P-value

Extrafine BDP
(n=189)

Fluticasone
(n=189)

P-valuea

201 (60.2)
66.5 (8.4)
26.4 (5.5)

201 (60.2)
66.6 (8.1)
26.1 (4.7)

n/a
0.61
0.46

108 (57.1)
67.2 (8.3)
26.5 (5.2)

108 (57.1)
67.1 (8.6)
26.6 (5.5)

n/a
0.79
0.66

205 (61.4)
70 (21.0)
28 (8.4)
31 (9.3)

195 (58.4)
67 (20.1)
46 (13.8)
26 (7.8)

0.48

119 (63.0)
30 (15.9)
26 (13.8)
14 (7.4)

100 (52.9)
47 (24.9)
21 (11.1)
21 (11.1)

0.13

165 (49.7)
167 (50.3)
2003.1 (2.3)

162 (48.8)
170 (51.2)
2002.8 (2.3)

0.81

78 (41.5)
110 (58.5)
2002.7 (2.2)

0.74

,0.001

75 (39.9)
113 (60.1)
2003.3 (2.2)

183 (54.8)
38 (11.4)
49 (14.7)
70 (21.0)

187 (56.0)
48 (14.4)
54 (16.2)
45 (13.5)

0.74
0.25
0.58
0.010

141 (74.6)
28 (14.8)
26 (13.8)
45 (23.8)

145 (76.7)
31 (16.4)
30 (15.9)
34 (18.0)

0.63
0.63
0.56
0.15

131 (39.2)
81 (24.3)
122 (36.5)

131 (39.2)
81 (24.3)
122 (36.5)

n/a

73 (38.6)
33 (17.5)
83 (43.9)

73 (38.6)
33 (17.5)
83 (43.9)

n/a

39 (11.7)

28 (8.4)

–

29 (15.3)

26 (13.8)

300 (89.8)
52.9 (17.9)
202 (67.3)

280 (83.8)
52.5 (18.7)
193 (68.9)

–
0.90
–

169 (89.4)
55.3 (19.3)
101 (59.8)

163 (86.2)
52.4 (17.9)
108 (66.3)

–
0.21
–

15 (5.4)
126 (45.5)
106 (38.3)
30 (10.8)

19 (7.2)
109 (41.3)
104 (39.4)
32 (12.1)

0.75

12 (7.9)
73 (48.0)
51 (33.6)
16 (10.5)

7 (4.5)
74 (47.7)
51 (32.9)
23 (14.8)

0.12

128 (38.3)
26 (7.8)
136 (40.7)

0.027

88 (46.6)
11 (5.8)
35 (18.5)

77 (40.7)
5 (2.6)
52 (27.5)

0.057

 SAMA + SABA

154 (46.1)
22 (6.6)
114 (34.1)

 LABA ± SAMA ± SABA

33 (9.9)

33 (9.9)

51 (27.0)

51 (27.0)

 LAMA ± SAMA ± SABA

7 (2.1)

7 (2.1)

2 (1.1)

2 (1.1)

 LAMA + LABA ± SAMA ± SABA
Other
LABA during baseline year, n (%)
COPD prescriptions, median (IQR)
Mean daily ICS dose, n (%)b,d

1 (0.3)

1 (0.3)

2 (1.1)

2 (1.1)

3 (0.9)
37 (11.1)
6 (3–10)

3 (0.9)
35 (10.5)
6 (3–11)

0.47
0.60

0
53 (28.0)
9 (5–13)

0
53 (28.0)
10 (6–14)

n/a
0.16

1–50 μg/d

–

–

n/a

20 (10.6)

11 (5.8)

0.13

51–100 μg/d

–

–

47 (24.9)

46 (24.3)

101–200 μg/d

–

–

51 (27.0)

60 (31.7)

51 (27.0)

49 (25.9)

20 (10.6)

23 (12.2)

Male sex, n (%)b
Age at index date, mean (SD)b
BMI in kg/m2, mean (SD)c
Charlson comorbidity index score, n (%)
0
1
2
$3
Current smoker, n (%)
Ex-smoker, n (%)
Index prescription date, mean (SD)b
Recorded comorbidity, n (%)
 Asthma diagnosis
 Rhinitis diagnosis
 GERD diagnosis
Cardiac disease diagnosis
Exacerbations, n (%)b
0 (COPD treatment success)
1
$2
Patients with $4 exacerbations
Recorded %predicted FEV1, n (%)
%predicted FEV1, mean (SD)
%predicted FEV1 ,60%, n (%)
GOLD grade22,c, n (%)
 GOLD 1
 GOLD 2
 GOLD 3
 GOLD 4
Baseline therapy, n (%)b
 SABA
 SAMA

a

201–400 μg/d
.400 μg/d
Oral candidiasis,e diagnosis/Rx, n (%)
$1 inpatient admission for COPD/lower
respiratory condition, n (%)
Antibiotic prescriptions for LRTI, n (%)
0 prescription
1 prescription

,0.001

–

–

10 (3.0)
4 (1.2)

11 (3.3)
6 (1.8)

0.82
0.53

10 (5.3)
1 (0.5)

5 (2.6)
1 (0.5)

0.15
1.0

218 (65.3)
64 (19.2)

216 (64.7)
80 (24.0)

0.39

123 (65.1)
37 (19.6)

121 (64.0)
36 (19.0)

0.67

(Continued)
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Table 1 (Continued)
Characteristic

$2 prescriptions
 All patients with $4 prescriptions

Initiation sample

Step-up sample

Extrafine BDP
(n=334)

Fluticasone
(n=334)

52 (15.6)
13 (3.9)

38 (11.4)
5 (1.5)

P-value

a

–

Extrafine BDP
(n=189)

Fluticasone
(n=189)

29 (15.3)
3 (1.6)

32 (16.9)
10 (5.3)

P-valuea

–

Notes: aMatched cohorts were compared using conditional logistic regression; bmatching variable (age matching was ±5 years and index prescription date ±1 year for the
initiation sample and ±2 years for the step-up sample); crecorded BMI data were available for 331 (99%) and 328 (98%) patients in extrafine beclomethasone and fluticasone
initiation cohorts, respectively, and for 185 (98%) and 184 (97%) patients in extrafine beclomethasone and fluticasone step-up cohorts, respectively. Recorded GOLD severity
data were available for 277 (83%) and 264 (79%) patients in extrafine beclomethasone and fluticasone initiation cohorts, respectively, and for 152 (80%) and 155 (82%)
patients in extrafine beclomethasone and fluticasone step-up cohorts, respectively; dthe doses of ICS were standardized to equivalence with extrafine beclomethasone and
fluticasone; thus, baseline doses of large-particle beclomethasone and budesonide were halved. The daily dose was calculated as the number of days’ supply divided by number
of prescription days; eoral candidiasis was identified through coded diagnosis or therapy for same, namely, oral antifungal prescriptions.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; diagnosis/Rx, coded diagnosis or therapy for
same; FEV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled
corticosteroid; IQR, interquartile range; n/a, not applicable; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LRTI, lower respiratory tract infection;
Rx, therapy; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.

Prescribed index date doses of extrafine beclomethasone
were significantly lower than those of fluticasone (median
interquartile range [IQR], 200 [200–400] versus 500 [500–
1,000] µg/d; P,0.001; Figure 1).
There were no significant differences between cohorts
in the unadjusted or adjusted coprimary outcome measures
(Table 2). Exacerbation rates fell during the 2 year outcome
period relative to baseline in both cohorts (Figure 2 and
Table 3); one third of patients in each cohort experienced
COPD treatment success (no COPD exacerbation during
the 2 outcome years).
The adjusted odds of treatment stability (no exacerbation or treatment change) were significantly better for
extrafine beclomethasone (adjusted odds ratio [OR], 2.50;
95% confidence interval [CI], 1.32–4.73), mainly driven by
significantly lower odds of treatment change in that cohort
(Table 2). Treatment changes during the outcome period are
depicted in Figure 3. An increase in ICS dose by $50% was
significantly more frequent in the extrafine beclomethasone
cohort, while additional therapy was significantly more frequent in the fluticasone cohort (Table 2). The mean daily ICS
dose exposure during outcome was significantly lower in the
extrafine beclomethasone cohort (Table 2 and Figure 4).
A higher percentage of patients in the extrafine beclomethasone cohort had two or more lower respiratory tract
infections requiring antibiotic therapy (P=0.020), while
hospitalizations for COPD and lower respiratory conditions
were infrequent in both cohorts (Table 2). A total of seven
(2.1%) and four (1.2%) patients in extrafine beclomethasone
and fluticasone cohorts had a recorded diagnosis of pneumonia (P=0.37); we considered the diagnosis confirmed
for three (0.9%) patients in each cohort. There was no difference between cohorts in the adjusted odds of developing
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oral candidiasis, experienced by roughly one in ten patients
(Table 2).

Step-up sample
The extrafine beclomethasone and fluticasone cohorts were
similar at baseline, with mean age of 67 years and 57% male
(Tables 1 and S3). A significant difference between cohorts
in index date was small and not clinically meaningful (2003.3
versus 2002.7; P,0.001).
The stepped-up ICS dose prescribed at the index date
was significantly lower for extrafine beclomethasone than
fluticasone (median [IQR] 400 [400–400] versus 1,000
[500–1,000] µg/d; P,0.001; Figure 1).
Unadjusted and adjusted results for effectiveness measures were comparable for the two step-up cohorts during
the 2 year outcome period (Tables 3 and 4). As for the initiation sample, fewer patients in both cohorts experienced $2
exacerbations/year relative to baseline (Figure 2). Adjusted
odds of treatment stability and treatment change were similar
in the two cohorts (Table 4 and Figure 3). Mean daily ICS
dose exposure was significantly lower for extrafine beclomethasone (Table 4 and Figure 4).
The percentages of patients with lower respiratory tract
infection requiring antibiotic therapy were similar in the two
cohorts (Table 4); pneumonia was confirmed for two (1.1%)
patients in each cohort.

Additional analyses
Baseline patient characteristics were broadly similar for
the matched and full unmatched patient cohorts (Table S4),
and the unmatched results supported those for the matched
cohorts (see Supplementary material). In post hoc sensitivity
analyses, relative ICS doses and exacerbation rates among
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A

Extrafine BDP
50

FP

48

45

Percentage of patients

40

40

37

37

35
30
25
20
15

12

12

10
5
0

6
1

2

50

100

1

1

0

1

2

2

0

200 250 300 375 400 500 600 750 800 1,000 1,500 2,000

Daily dose (µg/d) of extrafine BDP or FP

B

Extrafine BDP

FP

80
71

Percentage of patients

70
60

51
50
42
40
30
20

15

10
0

50

100

1

2

200

250

2
300

400

500

5

7

600

800 1,000 1,500 2,000

2

3

Daily dose (µg/d) of extrafine BDP or FP
Figure 1 Daily dose of extrafine beclomethasone and larger-particle fluticasone as prescribed on the index date for (A) the initiation sample and (B) the step-up sample.
Notes: P,0.001 for the differences between cohorts. Percentages may not add up to 100% because of rounding; x-axis not to scale.
Abbreviations: BDP, beclomethasone dipropionate; FP, fluticasone propionate.

unmatched patients without a treatment change during the
outcome period were similar to findings in the main analyses
(Tables S5 and S6).
There was no significant difference between the two
treatment cohorts of initiation or step-up samples in all-cause
mortality after the outcome period (Table S7).

Discussion
We observed that COPD exacerbation rates in both initiation
and step-up samples during the 2 year outcome period were
1168
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comparable between matched cohorts prescribed extrafine
beclomethasone or larger-particle fluticasone in this retrospective analysis. For patients initiating ICS for COPD, those
prescribed extrafine beclomethasone had over twice the odds of
treatment stability (no COPD exacerbation or treatment change)
and half the odds of a treatment change. Index date prescribed
doses of extrafine beclomethasone were significantly lower
than doses of fluticasone, and the ICS dose exposure during the
outcome period was significantly lower for both the initiation
and step-up extrafine beclomethasone cohorts.
International Journal of COPD 2014:9
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Table 2 Unadjusted and adjusted results during the 2 year outcome period for the matched cohorts of the initiation sample
Outcome

Coprimary outcome measures
COPD treatment success (0 exacerbations)
 Exacerbations over 2 years
   0
   1
   2–3
   4–6
   $7
Secondary outcome measures
Time to first exacerbation, median (95% CI), days
Treatment stability (no Rx change or additional Rx)
Treatment change
Oral candidiasis, diagnosis/Rx

Extrafine BDP
(n=334)

Fluticasone
(n=334)

Unadjusted odds,
hazard, or rate
ratio for extrafine
BDP (95% CI)

Adjusted odds,
hazard, or rate
ratio for extrafine
BDP (95% CI)

118 (35.3)

119 (35.6)

118 (35.3)
70 (21.0)
66 (19.8)
49 (14.7)
31 (9.3)

119 (35.6)
72 (21.6)
83 (24.9)
30 (9.0)
30 (9.0)

OR 0.98 (0.70–1.39)
RR 1.05 (0.86–1.30)
–
–
–
–
–

aOR 1.01 (0.70–1.46)b
aRR 1.07 (0.87–1.33)c
–
–
–
–
–

419 (315–523)
66 (19.8)
183 (54.8)
28 (8.4)

413 (306–520)
52 (15.6)
209 (62.6)
36 (10.8)

HR 1.07 (0.84–1.35)
OR 1.40 (0.91–2.16)
OR 0.71 (0.51–0.98)
RR 1.04 (0.53–2.01)

aHR 1.02 (0.79–1.32)d
aOR 2.50 (1.32–4.73)e
aOR 0.49 (0.32–0.75)f
aRR 1.06 (0.59–1.90)g

P-valuea
Disaggregated outcome measures
1 oral corticosteroid course
$2 oral corticosteroid courses
1 lower respiratory infection + antibiotic Rx
$2 lower respiratory infections + antibiotic Rx
$1 hospitalization for COPD or lower respiratory
Daily ICS dose (μg/d), median (IQR)
Daily SABA dose (μg/d), median (IQR)
Increase in ICS dose by $50%
Additional new therapy

58 (17.4)
56 (16.8)
69 (20.7)
89 (26.6)
12 (3.6)
315 (151–459)
822 (384–1,534)
96 (28.7)
157 (47.0)

51 (15.3)
52 (15.6)
72 (21.6)
63 (18.9)
9 (2.7)
436 (206–740)
918 (384–1,534)
68 (20.4)
194 (58.1)

0.44

–

0.020

–

0.49
,0.001
0.22
0.017
0.002

–
–
–
–
–

Notes: Data are n (%) unless otherwise indicated. Treatment change was defined as the first change and could include an increase in ICS dose and/or additional therapy.
Additional new therapy was new for those patients and could be at any time during the 2 outcome years; patients could have received $1 additional therapy. aConditional
logistic regression. Adjusted for baseline: btheophylline prescriptions and GERD diagnosis and/or therapy; cantibiotics use, LABA, number of primary care consultations, and
year of first coded diagnosis at practice; drhinitis diagnosis, amitriptyline, antibiotics use, number of COPD prescriptions, and time from first coded diagnosis at practice to
index date; eyear of index date; fyear of index date and time from first coded diagnosis at practice to index date; gcardiac disease diagnosis, GERD diagnosis and/or therapy,
number of COPD prescriptions, and oral candidiasis.
Abbreviations: aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; diagnosis/Rx, coded diagnosis or therapy for same; ICS, inhaled corticosteroid; IQR, interquartile range; Rx, treatment; SABA, short-acting
β2-agonist; OR, odds ratio; HR, hazard ratio; RR, rate ratio; GERD, gastroesophageal reflux disease; LABA, long-acting β2-agonist.

The percentages of patients in each cohort who
experienced $2 exacerbations/year fell substantially during
the outcome period. Relative to the baseline year, 11%–13%
fewer patients in each initiation cohort, and 9%–16% fewer
in each step-up cohort, experienced $2 exacerbations/year.
This finding suggests that pharmacotherapy was effective, as
the experience of frequent COPD exacerbations ($2/year)
is reportedly a relatively stable patient phenotype.24 These
findings suggest, moreover, that increasing the dose of ICS
can improve outcomes for some patients. Nonetheless,
25%–28% of patients in the extrafine beclomethasone cohorts
and 18%–31% in fluticasone cohorts experienced $4 exacerbations during the 2 year outcome period.
Although ICS are not recommended in COPD other than
in fixed-dose combination with LABA, several studies have
demonstrated some efficacy of ICS with regard to clinical outcomes,25 and practice surveys in developed countries indicate
International Journal of COPD 2014:9

that prescribing of ICS outside of fixed-dose combinations
is not infrequent in usual care.11–13 (Moreover, fluticasone is
licensed in some countries, including the Netherlands, for
COPD). In this study, from 40%–49% of patients in initiation
cohorts and from 33%–35% in step-up cohorts remained on
ICS monotherapy at the end of the 2 year outcome period, not
an ideal situation according to guideline recommendations
but a reality of clinical practice and perhaps a reflection of
earlier COPD treatment guidelines.
There is little other published work comparing ICS with
different particle sizes for COPD. Two studies have compared combination ICS/LABA products.26,27 In a 12 week
double-blind study of 18 patients with lung hyperinflation,
the combination of extrafine beclomethasone/formoterol, but
not larger-particle-size fluticasone/salmeterol, was effective
in reducing air trapping and dyspnea.26 This concurs with our
findings that the cohort initiating extrafine-particle ICS was
submit your manuscript | www.dovepress.com
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Figure 2 Percentage of patients experiencing 0, 1, or ≥2 COPD exacerbations during the baseline year and years 1 and 2 of the 2 year outcome period in (A) the initiation
sample and (B) the step-up sample.
Abbreviations: COPD, chronic obstructive pulmonary disease; BDP, beclomethasone dipropionate.

less frequently prescribed a treatment change than the cohort
initiating larger-particle-size ICS. In another study, clinical
outcomes for 232 patients prescribed beclomethasone/formoterol were similar to those for 238 patients prescribed
larger-particle budesonide/formoterol with regard to COPD
questionnaires and overall low exacerbation rates, while
FVC improved more in those prescribed beclomethasone/
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formoterol.27 The FVC results observed, and those of the prior
study,26 could perhaps be explained by better distribution of
extrafine particles to the small peripheral airways, an important site of inflammation in COPD.4,15,16
Further investigations and mechanistic studies are needed
to explore the comparative effects of differing ICS particle
sizes for treating COPD, including prospective pragmatic
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Table 3 Exacerbation rates during baseline and outcome periods
Exacerbations

Initiation sample

Baseline year, mean (SD)
Median (IQR)
Outcome year 1, mean (SD)
Median (IQR)
Outcome year 2, mean (SD)
Median (IQR)

Step-up sample

Extrafine BDP
(n=334)

Fluticasone
(n=334)

P-value

Extrafine BDP
(n=189)

Fluticasone
(n=189)

P-valuea

1.4 (1.8)
1 (0–2)
1.18 (1.89)
0 (0–2)
1.14 (1.90)
0 (0–2)

1.4 (1.8)
1 (0–2)
1.07 (1.73)
0 (0–2)
1.13 (2.01)
0 (0–1)

0.47

1.7 (2.0)
1 (0–2)
1.46 (2.01)
1 (0–2)
1.32 (1.91)
1 (0–2)

1.7 (2.0)
1 (0–2)
1.31 (1.92)
1 (0–2)
1.51 (2.09)
1 (0–2)

1.0

a

0.43
0.95

0.47
0.33

Note: aMatched cohorts were compared using conditional logistic regression.
Abbreviations: BDP, beclomethasone dipropionate; IQR, interquartile range; SD, standard deviation.
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Figure 3 Changes in treatment and ICS dose during the 2 year outcome period for the (A) extrafine beclomethasone initiation cohort, (B) fluticasone initiation cohort,
(C) extrafine beclomethasone step-up cohort, (D) fluticasone step-up cohort.
Note: “Other” includes LTRA and theophylline.
Abbreviations: BDP, beclomethasone dipropionate; FDC, fixed-dose combination ICS-LABA; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist; LTRA, leukotriene receptor antagonist.

trials of ICS administered concomitantly with long-acting
bronchodilators. The identification of surrogate markers of
small airway inflammation evaluable in both smokers and
ex-smokers would aid this process. Recent work suggests
that alveolar nitric oxide (NO) is not a useful marker for
monitoring response to COPD therapy.28
Our composite exacerbation definition included lower
respiratory tract antibiotic therapy (or an oral corticosteroid course or unscheduled hospitalization or ED visit).
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At least one antibiotic prescription for lower respiratory
tract infection was prescribed during the 2 year follow-up
for 47% of patients initiating extrafine beclomethasone and
40% initiating fluticasone, a statistically significant difference, which may need further study to assess whether this is
a real observation. Of note, we found the opposite direction
of effect in the step-up cohorts (although the difference was
not statistically significant), as 49% and 56% of extrafine
beclomethasone and fluticasone patients, respectively,
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Figure 4 Mean daily ICS dose exposure for extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period by (A) the initiation sample and (B) the
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Notes: P,0.001 for the differences between cohorts. Percentages may not add up to 100% because of rounding. The mean daily dose exposure for each patient was
calculated as the number of days’ supply divided by 730.
Abbreviations: BDP, beclomethasone dipropionate; FP, fluticasone propionate; ICS, inhaled corticosteroid.

received one or more antibiotic prescriptions. The fact of
the results being in opposite directions could potentially be
explained by the distribution of outliers during the baseline
year, as patients with a higher number of baseline antibiotic
prescriptions may be more likely to need antibiotic therapy
during the outcome period: namely, in the initiation sample
during baseline, 13 patients in the extrafine beclomethasone

International Journal of COPD 2014:9

cohort versus five in the fluticasone cohort received from 4–8
courses of antibiotics; and in the step-up sample during baseline, three versus ten, respectively, received from 4–7 courses
of antibiotics.
In addition to effectiveness of ICS it is important to
assess side effects.1 Confirmed pneumonia was infrequent
and comparable with both ICS treatments, recorded for three

submit your manuscript | www.dovepress.com

Dovepress

1173

Dovepress

Postma et al

Table 4 Unadjusted and adjusted results during the 2 year outcome period for the matched cohorts of the step-up sample
Outcome

Coprimary outcome measures
COPD treatment success (0 exacerbations)
 Exacerbations over 2 years
   0
   1
   2–3
   4–6
   $7
Secondary outcome measures
Time to first exacerbation, median (95% CI), days
Treatment stability (no Rx change or additional Rx)
Treatment change
Oral candidiasis, diagnosis/Rx

Extrafine BDP
(n=189)

Fluticasone
(n=189)

Unadjusted odds,
hazard, or rate
ratio for extrafine
BDP (95% CI)

Adjusted odds,
hazard, or rate
ratio for extrafine
BDP (95% CI)

58 (30.7)

50 (26.5)

58 (30.7)
32 (16.9)
47 (24.9)
27 (14.3)
25 (13.2)

50 (26.5)
36 (19.0)
44 (23.3)
40 (21.2)
19 (10.1)

OR 1.33 (0.79–2.26)
RR 0.98 (0.78–1.24)
–
–
–
–
–

aOR 1.45 (0.70–3.00)b
aRR 0.98 (0.79–1.23)c
–
–
–
–
–

313 (222–404)
36 (19.0)
102 (54.0)
17 (9.0)

289 (192–386)
25 (13.2)
111 (58.7)
19 (10.1)

HR 0.96 (0.71–1.31)
OR 1.65 (0.90–3.01)
OR 0.84 (0.57–1.24)
RR 1.96 (0.83–4.62)

aHR 0.97 (0.70–1.34)d
aOR 1.68 (0.78–3.59)e
aOR 0.75 (0.48–1.18)f
aRR 1.06 (0.54–2.06)g

P-valuea
Disaggregated outcome measures
1 oral corticosteroid course
$2 oral corticosteroid courses
1 lower respiratory infection + antibiotic Rx
$2 lower respiratory infections + antibiotic Rx
$1 hospitalization for COPD or lower respiratory
Daily ICS dose (μg/d), median (IQR)
Daily SABA dose (μg/d), median (IQR)
Increase in ICS dose by $50%
Additional new therapy

24 (12.7)
51 (27.0)
46 (24.3)
46 (24.3)
8 (4.2)
438 (274–619)
1,041 (548–1,671)
28 (14.8)
100 (52.9)

32 (16.9)
50 (26.5)
53 (28.0)
52 (27.5)
3 (1.6)
534 (329–843)
1,096 (493–1,808)
21 (11.1)
105 (55.6)

0.71

–

0.22

–

0.15
,0.001
0.29
0.28
0.62

–
–
–
–
–

Notes: Data are n (%) unless otherwise indicated. Treatment change was defined as the first change and could include an increase in ICS dose and/or additional therapy.
Additional new therapy was new for those patients and could be at any time during the 2 outcome years; patients could have received $1 additional therapy. aConditional
logistic regression. Adjusted for baseline: badherence to ICS therapy, number of primary care consultations, and time from first coding of COPD at practice to index date;
c
adherence to ICS therapy and no primary care consultations; dnumber of primary care consultations; eGERD diagnosis and/or therapy and adherence to ICS; fGERD diagnosis
and/or therapy and adherence to ICS; gbeta blockers, GERD diagnosis and/or therapy, adherence to ICS therapy, and oral candidiasis.
Abbreviations: aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic
obstructive pulmonary disease; diagnosis/Rx, coded diagnosis or therapy for same; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; Rx, treatment; SABA,
short-acting β2-agonist; IQR, interquartile range; OR, odds ratio; HR, hazard ratio; RR, rate ratio.

patients in each initiation cohort and one in each step-up
cohort. However, the incidence of pneumonia may have been
underestimated in this study, as some cases of pneumonia
may have been coded as lower respiratory tract infection
and treated in the home setting. Moreover, it is possible that
some hospitalizations for pneumonia were not captured in
the database. The post-study all-cause mortality rates did not
differ between cohorts.
Observational research provides important insights into
the realities of real-life practice. For instance, although
extrafine beclomethasone is not approved for use in COPD,
this analysis shows that it is widely prescribed for patients
with COPD in general practice. The effectiveness and safety
information provided in this analysis for patients with COPD
prescribed extrafine beclomethasone is a novel and valuable
addition to the literature. Observational research also enables
the study of heterogeneous patient populations in real-life
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clinical care conditions, providing relevant information
to complement that from tightly controlled and selective
randomized clinical trials.29,30 This matched cohort study
included a broad range of patients who were prescribed
COPD therapy under usual conditions of care in UK general practice. The fact that baseline patient characteristics
were broadly similar for matched and unmatched patient
groups suggests that studied patients were representative
of the general UK COPD population. The inclusive patient
population enhances external validity of findings and their
generalizability to real-life practice. In addition, we followed
patients for 2 years, allowing us to describe the course of
therapy over this time period.
A high percentage of patients in this study, $55% in each
treatment cohort, also had a diagnosis of asthma recorded in
the database (after the age of 40, per inclusion criteria). This
may reflect the fact that a subgroup of patients with asthma

International Journal of COPD 2014:9

Dovepress

develops persistent airway obstruction over time, particularly
when they smoke.31 We believe that the COPD diagnosis was
valid for most patients under study for several reasons: 1) all
patients had a recorded post-bronchodilator FEV1/FVC ratio
of ,0.7; 2) all were smokers or ex-smokers; 3) the mean age
was 67 years, and the cohorts included a preponderance of
men (60%); 4) among those with an FEV1 reading at baseline
(87% of the full population studied), the mean %predicted
FEV1 in the four cohorts ranged from 52% to 55% (depending
on cohort); and from 60% to 69% of patients in each cohort
had a %predicted FEV1 of ,60%; 5) moreover, of the patients
with an asthma codiagnosis, most also had substantial FEV1
impairment (mean FEV1 %predicted, 53%; data not shown);
6) finally, the COPD diagnosis was recorded at or close to
the time of the asthma diagnosis for most patients, and,
importantly, the COPD diagnosis was confirmed (via FEV1/
FVC ratio ,0.7) for most patients after the asthma diagnosis was recorded (Figure S3). This suggests that the asthma
codiagnosis was often an initial misdiagnosis that was later
superseded by a diagnosis of COPD.
Retrospective studies such as this one are limited by the
available data. All included patients had a database-recorded
post-bronchodilator FEV1/FVC ,0.7; however, we were
unable to track lung function during the outcome period
because spirometry is not performed routinely in primary
care. Moreover, not all potential matching criteria were available for all patients at baseline, including the FEV1 value
(hence GOLD grade) and scores for the modified Medical
Research Council or COPD Assessment Test, which would
have enabled patient categorization according to recent
GOLD guidelines.1 Nonetheless, patients appeared to be
well-matched for physical characteristics and disease severity, and the analyses incorporated adjustments for residual
confounding (although we cannot rule out unidentified confounding factors). Finally, the percentages of patients in each
cohort who quit smoking during the outcome period would
have been of interest, since the effects of ICS can be less in
smokers with COPD.

Conclusion
This study has enabled us to describe the use of ICS for
patients with COPD in UK primary care. We observed that
ICS are prescribed, both as monotherapy and in combination
with long-acting bronchodilators, for treating COPD and
can result in improved exacerbation rates as in our COPD
patients with predominantly GOLD grade 2 and 3 severity
of airflow limitation. Our observations that small-particle
ICS at significantly lower doses had the same effects as
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larger-particle ICS at higher doses and that small-particle
ICS use was associated with greater odds of treatment stability and lower odds of treatment change during the 2 year’
follow-up could be explained by greater lung deposition,
especially to the small airways. Future pragmatic trials are
needed to prospectively evaluate the effectiveness of ICS of
differing particle sizes in COPD, administered concomitantly
with long-acting bronchodilators.
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Supplementary materials
Results for unmatched patient
populations

• For the unmatched patients: prescribed inhaled corticosteroids doses were significantly lower for extrafine
beclomethasone in both
○ initiation sample: median interquartile range [IQR],
200 [200–400] versus fluticasone 500 [500–1000] µg/d;
P,0.001, and
○ step-up sample: median [IQR], 400 [400–400] versus
fluticasone 1,000 [500–1,000] µg/d; P,0.001.
• For the unmatched patients: primary outcome measures
showed no significant difference between cohorts in
COPD exacerbation rate during outcome, with adjusted
rate ratio
○ for initiation sample: 1.04 (95% confidence interval
[CI], 0.89–1.22) for extrafine beclomethasone relative
to fluticasone
○ step-up sample: 0.94 (95% CI, 0.80–1.10) for extrafine
beclomethasone.
• For the unmatched patients: there was no significant
difference between cohorts in odds of COPD treatment
success during outcome, with adjusted odds ratio
○ for initiation sample: 0.99 (95% CI, 0.77–1.29) for
extrafine beclomethasone relative to fluticasone
○ step-up sample: odds ratio 1.20 (95% CI, 0.83–1.72)
for extrafine beclomethasone.

Table S1 Chronic respiratory diseases and database codes that
were cause for study exclusion
NHS read code

NHS read term

AD5..00
H4...00
H4...11
H4...12
H40..00
H41..00
H410.00
H41z.00
H42..00
H420.00
H421.00
H422.00
H423.00
H42z.00
H43..00
H431.00
H432.00
H433.00
H434.00
H435.00
H43z.00
H44..00
H440.00
H441.00
H44z.00
H45..00
H450.00
H46..00
H460.00
H460z00
H464.00
H464100
H464200
H464z00
H46z.00
H46zz00
H48..00
H4y..00
H4y1.00
H4y1000
H4y1z00
H4y2.00
H4y2100
H4yy.00
H4yz.00
H4z..00
H57y200

Sarcoidosis
Lung disease due to external agents
Pneumoconiosis
Occupational lung disease
Coal workers’ pneumoconiosis
Asbestosis
Pleural plaque disease/asbestosis
Asbestosis NOS
Silica/silicate pneumoconiosis
Talc pneumoconiosis
Simple silicosis
Complicated silicosis
Massive silicotic fibrosis
Silica pneumoconiosis NOS
Pneumoconiosis-other inorganic dust
Bauxite fibrosis of lung
Berylliosis
Graphite fibrosis of lung
Siderosis
Stannosis
Pneumoconiosis-inorganic dust NOS
Pneumopathy-other dust inhalation
Byssinosis
Cannabinosis
Pneumopathy-dust inhalation NOS
Pneumoconiosis NOS
Pneumoconiosis associated with tuberculosis
Respiratory disease – chemical fumes
Chemical bronchitis/pneumonitis
Chemical bronchitis/pneumonitis NOS
Chronic chemical respiratory conditition
Chemical obliterative bronchiolitis
Chemical pulmonary fibrosis
Chronic chemical respiratory condition NOS
Chemical respiratory conditions NOS
Chemical respiratory conditions NOS
Progressive massive fibrosis
External agent lung disease OS
Chronic pulmonary radiation disease
Radiation pulmonary fibrosis
Chronic pulmonary radiation disease NOS
Drug-induced interstitial lung disorder
Chronic drug-induced interstitial lung disorder
Other external agent respiratory condition
External agent respiratory condition NOS
External agent lung disease NOS
Pulmonary sarcoidosis

Abbreviations: NHS, National Health Service; NOS, not otherwise specified;
OS, otherwise stated.
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Table S2 List of potential confounding variables considered for
this study
• The index date
Potential confounders examined at (or closest to) the relevant
index date
• Age
• Sex
• Height
• Weight
• Body mass index
• Lung function, in terms of spirometry before index date
• Smoking status
Potential confounders examined regardless of when they
occurred relative to the index date
• Date of first COPD diagnosis (where known)
• Other respiratory or other confounding diagnoses, including rhinitis,
gastroesophageal reflux disease, and cardiac disease
Potential confounders examined in the year before
the index date
• Other important unrelated comorbidities expressed using the
Charlson Comorbidity Index, calculated over the 1 year baseline
period
• Number of general practice consultations for COPD or other
respiratory illness
• Number of hospital outpatient attendances where COPD is recorded
as the reason for referral
• Number of hospitalizations or emergency department attendance for
COPD or possibly respiratory-related (a non-specific hospitalization
code and a COPD/respiratory code within a 1 week window)
• Number of acute courses of oral corticosteroids
• Number of prescriptions for any antibiotic where the reason for the
prescription is lower respiratory tract infection
• Other medications that might interfere with COPD control, including
beta-blockers, NSAIDs, acetaminophen, and antidepressants
• Prior treatment classified as
○ No drug therapy
○ SABA only
○ SAMA ± SABA
○ LABA ± SAMA ± SABA
○ LAMA ± SAMA ± SABA
○ LAMA ± LABA ± SAMA ± SABA
• Average ICS daily dose during baseline year
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled
corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic
antagonist; NSAID, nonsteroidal anti-inflammatory drug; SABA, short-acting
β2-agonist; SAMA, short-acting muscarinic antagonist.

International Journal of COPD 2014:9

submit your manuscript | www.dovepress.com

Dovepress

1179

Dovepress

Postma et al

Table S3 Additional baseline patient characteristics by matched treatment cohort
Characteristic

Initiation sample
Extrafine BDP
(n=334)

Timing of COPD diagnosis code in database, n (%)
52 (15.6)
.3 yr before index date
6 mo to 3 yr before index date
82 (24.6)
102 (30.5)
 At or ,6 mo before index date
66 (19.8)
,3 yr after index date
32 (9.6)
$3 yr after index date
BMI category, n (%)b
14 (4.2)
Underweight (BMI ,18.5 kg/m2)
132 (39.9)
 Normal (BMI 18.5–,24.5 kg/m2)
115 (34.7)
Overweight (BMI 24.5–,30 kg/m2)
70 (21.1)
Obese (BMI $30 kg/m2)
$1 prescription in baseline year or at index date, n (%)
Beta blocker
37 (11.1)
 NSAID
134 (40.1)
Paracetamol
114 (34.1)
 Antidepressant
47 (14.1)
Daily SABA dose, median (IQR)
219 (110–548)
Daily SAMA dose, median (IQR)
0 (0–55)
Pneumonia diagnosis, confirmed, n (%)
0 (0)

Step-up sample
Fluticasone
(n=334)

P-value

Extrafine BDP
(n=189)

Fluticasone
(n=189)

P-valuea

63 (18.9)
81 (24.3)
117 (35.0)
40 (12.0)
33 (9.9)

0.13

50 (26.5)
32 (16.9)
33 (17.5)
41 (21.7)
33 (17.5)

57 (30.2)
43 (22.8)
28 (14.8)
31 (16.4)
30 (15.9)

0.17

15 (4.6)
125 (38.1)
121 (36.9)
67 (20.4)

0.96

5 (2.7)
75 (40.5)
67 (36.2)
38 (20.5)

6 (3.3)
78 (42.4)
57 (31.0)
43 (23.4)

0.84

35 (10.5)
113 (33.8)
123 (36.8)
65 (19.5)
219 (110–548)
11 (0–55)
3 (0.9)

0.80
0.082
0.47
0.049
0.77
0.16
n/a

19 (10.1)
81 (42.9)
75 (39.7)
35 (18.5)
384 (219–658)
0 (0–44)
1 (0.5)

9 (4.8)
70 (37.0)
72 (38.1)
27 (14.3)
438 (219–767)
0 (0–55)
0 (0)

0.056
0.26
0.72
0.11
0.22
0.40
n/a

a

Notes: aMatched cohorts were compared using conditional logistic regression; brecorded BMI data were available for 331 (99%) and 328 (98%) patients in extrafine
beclomethasone and fluticasone initiation cohorts, respectively, and for 185 (98%) and 184 (97%) patients in extrafine beclomethasone and fluticasone step-up cohorts,
respectively.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; n/a, not applicable;
NSAID, nonsteroidal anti-inflammatory drug; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; yr, years; mo, months.
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Table S4 Baseline characteristics of unmatched cohorts
Characteristic

Male sex, n (%)a
Age at index date, mean (SD)a
BMI in kg/m2, mean (SD)
Charlson comorbidity index score, n (%)
0
1
2
$3
Current smoker, n (%)
Ex-smoker, n (%)
Index prescription date, mean (SD)a
Recorded comorbidity, n (%)
 Asthma diagnosis
 Rhinitis diagnosis
 GERD diagnosis
Cardiac disease diagnosis
Exacerbations, n (%)b
0 (COPD treatment success)
1
$2
Recorded %predicted FEV1, n (%)
%predicted FEV1, mean (SD)
GOLD grade (2008 criteria), n (%)
 GOLD 1
 GOLD 2
 GOLD 3
 GOLD 4
Baseline therapy, n (%)a
 SABA
 SAMA
 SAMA + SABA
 LABA ± SAMA ± SABA
 LAMA ± SAMA ± SABA
 LAMA + LABA ± SAMA ± SABA
Other
LABA during baseline year, n (%)
COPD prescriptions, median (IQR)
Mean daily ICS dose, n (%)a,b
1–50 μg/d
51–100 μg/d
101–200 μg/d
201–400 μg/d
.400 μg/d
Oral candidiasis, diagnosis/Rx, n (%)
$1 Inpatient admission for COPD/lower
respiratory condition, n (%)
Antibiotics: 1 prescription, n (%)
$2 prescriptions, n (%)
Daily SABA dose, median (IQR)
Daily SAMA dose, median (IQR)
Pneumonia diagnosis, confirmed, n (%)

Initiation – unmatched

Step-up – unmatched

Extrafine BDP
(n=938)

Fluticasone
(n=443)

Extrafine BDP
(n=372)

Fluticasone
(n=606)

535 (57.0)
67.5 (9.5)
26.1 (5.2)

259 (58.5)
65.6 (8.8)
26.2 (4.8)

206 (55.4)
67.8 (10.1)
26.6 (5.2)

325 (53.6)
65.2 (9.5)
26.3 (5.3)

577 (61.5)
197 (21)
96 (10.2)
68 (7.2)
422 (46.1)
494 (53.9)
2004.4 (2.4)

268 (60.5)
84 (19)
58 (13.1)
33 (7.4)
209 (48.2)
225 (51.8)
2002.3 (2.6)

236 (63.4)
58 (15.6)
50 (13.4)
28 (7.5)
141 (39.1)
220 (60.9)
2004.2 (2.3)

360 (59.4)
121 (20.0)
70 (11.6)
55 (9.1)
267 (45.9)
315 (54.1)
2001.3 (2.8)

479 (51.1)
116 (12.4)
145 (15.5)
186 (19.8)

261 (58.9)
66 (14.9)
70 (15.8)
58 (13.1)

264 (71.0)
47 (12.6)
47 (12.6)
74 (19.9)

477 (78.7)
98 (16.2)
121 (20.0)
111 (18.3)

345 (36.8)
251 (26.8)
342 (36.5)
835 (89.0)
55.3 (18.5)

172 (38.8)
113 (25.5)
158 (35.7)
374 (84.4)
52.0 (18.9)

145 (39.0)
93 (25.0)
134 (36.0)
341 (91.7)
56.3 (19.9)

215 (35.5)
137 (22.6)
254 (41.9)
517 (85.3)
49.5 (18.7)

78 (9.1)
431 (50.1)
280 (32.5)
72 (8.4)

33 (8.5)
161 (41.6)
139 (35.9)
54 (14.0)

44 (12.7)
168 (48.4)
105 (30.3)
30 (8.6)

35 (6.7)
198 (37.6)
209 (39.7)
84 (16.0)

56 (6.0)
308 (32.8)
72 (7.7)
47 (5.0)
11 (1.2)
15 (1.6)
94 (10.0)
6 (3–10)
56 (6.0)
n/a
n/a
n/a
n/a
n/a
n/a
16 (1.7)
13 (1.4)

30 (6.8)
155 (35.0)
76 (17.2)
14 (3.2)
4 (0.9)
11 (2.5)
84 (19.0)
5 (3–11)
30 (6.8)
n/a
n/a
n/a
n/a
n/a
n/a
12 (2.7)
9 (2.0)

148 (39.8)
17 (4.6)
66 (17.7)
86 (23.1)
21 (5.6)
23 (6.2)
11 (3.0)
110 (29.6)
9 (5–13)

198 (32.7)
12 (2.0)
126 (20.8)
223 (36.8)
7 (1.2)
19 (3.1)
21 (3.5)
247 (40.8)
10 (6–14)

29 (7.8)
82 (22.0)
115 (30.9)
106 (28.5)
40 (10.8)
18 (4.8)
4 (1.1)

26 (4.3)
89 (14.7)
170 (28.1)
156 (25.7)
165 (27.2)
38 (6.3)
11 (1.8)

206 (22.0)
155 (16.5)
219 (110–548)
0 (0–44)
5 (0.5)

103 (23.3)
49 (11.1)
219 (110–548)
11 (0–55)
3 (0.7)

81 (21.8)
51 (13.7)
438 (164–712)
0 (0–44)
1 (0.3)

125 (20.6)
99 (16.3)
493 (219–877)
0 (0–66)
3 (0.5)

Notes: aMatching variable (age matching was ±5 years and index prescription date ±1 year for the initiation population and ±2 years for the step-up population); bthe doses
of ICS were standardized to equivalence with extrafine beclomethasone and fluticasone; thus, baseline doses of large-particle beclomethasone and budesonide were halved.
The daily dose was calculated as the number of days’ supply divided by number of prescription days.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; diagnosis/Rx, coded diagnosis or therapy for
same; FEV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled
corticosteroid; IQR, interquartile range; n/a, not applicable; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; NSAID, nonsteroidal anti-inflammatory
drug; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; SD, standard deviation.
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Table S5 Results during the 2 year outcome period for the initiation sample, unmatched cohorts, no treatment change
Outcome
Coprimary outcome measures
COPD treatment success (0 exacerbations)
 Exacerbations over 2 years
   0
   1
   2–3
   4–6
   $7
Secondary outcome measures
Time to first exacerbation, median (95% CI), days

Extrafine BDP
(n=413)

Fluticasone
(n=180)

Adjusted odds, hazard, or rate
ratio for extrafine BDP (95% CI)

170 (41.2)

79 (43.9)

OR 0.93 (0.64–1.37)b
RR 0.89 (0.66–1.20)c

170 (41.2)
98 (23.7)
83 (20.1)
46 (11.1)
16 (3.9)

79 (43.9)
40 (22.2)
36 (20.0)
8 (4.4)
17 (9.4)
HR 1.05 (0.82–1.34)d
P-valuea

Disaggregated outcome measures
1 oral corticosteroid course
$2 oral corticosteroid courses
1 lower respiratory infection + antibiotic Rx
$2 lower respiratory infections + antibiotic Rx
$1 hospitalization for COPD or lower respiratory
Daily ICS dose (μg/d), median (IQR)
Daily SABA dose (μg/d), median (IQR)
Increase in ICS dose by $50%
Continuing LABA from baseline
Confirmed pneumonia diagnosis

53 (12.8)
42 (10.2)
86 (20.8)
76 (18.4)
3 (0.7)
219 (110–356)
712 (329–1,315)
43 (10.4)
53 (12.8)
1 (0.2)

22 (12.2)
15 (8.3)
35 (19.4)
29 (16.1)
1 (0.6)
390 (138–740)
712 (274–1,452)
18 (10.0)
46 (25.6)
1 (0.6)

0.75
0.68
0.82
,0.001
0.70
0.88
Not applicable

Notes: Data are n (%) unless otherwise indicated. aConditional logistic regression. Adjusted for baseline: badjusted for: age, antibiotics use (with a lower respiratory read code
within a ±5 day window) (categorized), prescriptions for theophylline (Yes/No) and time between first coded diagnosis at practice and the index date (categorized); cadjusted
for: age, rhinitis diagnosis (Yes/No), antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized), acute use of oral steroids (categorized),
number of lower respiratory-related consultations (categorized), beta blockers (Yes/No), prescriptions for theophylline (Yes/No) and Year of first coded diagnosis at practice
(categorized); dadjusted for: age, antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized), number of COPD consultations (categorized),
prescriptions for theophylline (Yes/No) and inpatient admissions for COPD (Yes/No).
Abbreviations: HR, hazard ratio; OR, odds ratio; RR, rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic obstructive pulmonary disease;
ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; Rx, treatment; SABA, short-acting β2-agonist.
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Table S6 Unadjusted and adjusted results during the 2 year outcome period for the step-up sample, unmatched cohorts, no treatment
change
Outcome
Coprimary outcome measures
COPD treatment success (0 exacerbations)
 Exacerbations over 2 years
   0
   1
   2–3
   4–6
   $7
Secondary outcome measures
Time to first exacerbation, median (95% CI), days

Extrafine BDP
(n=178)

Fluticasone
(n=240)

Adjusted odds, hazard, or rate
ratio for extrafine BDP (95% CI)

65 (36.5)

86 (35.8)

OR 0.80 (0.50–1.29)b
RR 0.97 (0.74–1.26)c

65 (36.5)
43 (24.2)
39 (21.9)
19 (10.7)
12 (6.7)

86 (35.8)
37 (15.4)
55 (22.9)
37 (15.4)
25 (10.4)
HR 1.10 (0.85–1.42)d
P-valuea

Disaggregated outcome measures
1 oral corticosteroid course
$2 oral corticosteroid courses
1 lower respiratory infection + antibiotic Rx
$2 lower respiratory infections + antibiotic Rx
$1 hospitalization for COPD or lower respiratory
Daily ICS dose (μg/d), median (IQR)
Daily SABA dose (μg/d), median (IQR)
Increase in ICS dose by $50%
Continuing LABA from baseline
Confirmed pneumonia diagnosis

27 (15.2)
26 (14.6)
48 (27.0)
29 (16.3)
7 (3.9)
411 (219–575)
822 (329–1,315)
4 (2.2)
61 (34.3)
2 (1.1)

37 (15.4)
66 (27.5)
46 (19.2)
54 (22.5)
3 (1.3)
740 (432–1,027)
1,096 (438–1,781)
12 (5.0)
121 (50.4)
2 (0.8)

0.005
0.091
0.076
,0.001
0.002
0.15
0.001
0.76

Notes: Data are n (%) unless otherwise indicated. aConditional logistic regression. Adjusted for baseline: badjusted for: asthma diagnosis (Yes/No), GERD diagnosis and/or
therapy (Yes/No), cardiac disease diagnosis and/or therapy (Yes/No), acute use of oral steroids (categorized), number of primary care consultations (categorized), prior
LABA use (Yes/No) and time between first coded diagnosis at practice and the index date (categorized); cadjusted for: antibiotics use (with a lower respiratory read
code within a ±5 day window) (categorized), acute use of oral steroids (categorized), number of COPD consultations (categorized), average daily ICS dose (categorized),
prescriptions for paracetamol (Yes/No), prior LABA use (Yes/No) and time between first coded diagnosis at practice and IPD (categorized); dadjusted for: GERD diagnosis
and/or therapy (Yes/No), antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized 0–1/2+ to meet proportional hazards requirement), acute
use of oral steroids (categorized 0–1/2+ to meet proportional hazards requirement), prior LABA use (Yes/No) and number of primary care consultations (categorized).
Abbreviations: HR, hazard ratio; OR, odds ratio; RR, rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic obstructive pulmonary disease;
GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; Rx, treatment; SABA, short-acting β2-agonist.

Table S7 Post-study mortality rates
Initiation sample

Follow-up time in yearsa mean (SD)
Number of deaths, n (%)
All-cause mortality, adjusted HR (95% CI)

Step-up sample

Extrafine BDP
(n=334)

Fluticasone
(n=334)

Extrafine BDP
(n=189)

Fluticasone
(n=189)

6.6 (2.5)
58 (17.4)
1.07 (0.68–1.70)b

7.0 (2.6)
64 (19.2)
1.00

6.4 (2.3)
26 (13.8)
1.23 (0.61–2.47)c

7.2 (2.3)
39 (20.6)
1.00

Notes: The study was not designed to evaluate mortality rates during treatment, as patients had to be alive throughout the 2 year outcome period to be eligible for the
study. aFollow-up time from index date until censored or the end of the study period (end of 2010). Cox proportional hazards model: badjusted for Charlson comorbidity
index score and smoking status; cadjusted for age and cardiac disease diagnosis or therapy.
Abbreviations: BDP, beclomethasone dipropionate; CI, confidence interval; HR, hazard ratio; SD, standard deviation.
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Respiratory patients
in the GPRD and OPCRD
n=1,515,507

Inclusion criteria
Patients on ICS at any time post-1990
± ipratropium/salbutamol
± long-acting anticholinergic
± theophylline

Excluded
Patients not on any ICS therapy
(n=819,018)

Patients prescribed
any ICS inhalers
n=696,489

Excluded
-No recorded COPD diagnosis (n=588,951)
-Started on ICS before 1997 (n=36,935)
-Started ICS at age <40 years (n=2,028)
-Other chronic respiratory disease (n=897)
-Started on DPI, BAI, budesonide, or
ciclesonide (n=17,866)
-Prescribed an FDC ICS-LABA (n=1,235)
-Not registered at practice for 1 year before and
2 years after index date (n=13,090)

Patients prescribed
beclomethasone or fluticasone
n=35,487
Excluded
-<2 COPD Rx baseline year (n=20,496)
-Duplicated in GPRD and OPCRD (n=1,428)
-FEV1/FVC ratio >0.7 (n=1,466)
-On large-particle beclomethasone (n=9,825)
Matching criteria applied
-Same sex
-Age ±5 years
-Baseline year no COPD
exacerbations (0, 1, ≥2)
-Baseline Rx: (a) SABA/SAMA/
SABA + SAMA, (b) LABA,
(c) LAMA, (d) LABA+LAMA±SABA
±SAMA, or (e) other
-Year of index date ±1 year

Patients with COPD initiating
ICS therapy as:
Extrafine beclomethasone n=1,454
Fluticasone n=818
Lost on matching
Extrafine beclomethasone n=436
Fluticasone n=274
Randomize matching patients 1:1*
*Software used to randomly pick
unique matched patients

Double matches lost on
randomisation 1:1
Extrafine beclomethasone n=529
Fluticasone n=55

1:1 uniquely matched pairs: n=489
Excluded pairs
-COPD not confirmed by spirometry
(n=134)
-Non-smokers (n=20)
-Asthma diagnosis at <40 years old
(n=1)

Total matched patients included
Extrafine beclomethasone n=334
Fluticasone n=334

Figure S1 Patient selection and matching for the initiation sample.
Note: Patients in the two treatment cohorts were matched on clinically and demographically significant characteristics.
Abbreviations: BAI, breath-actuated inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; GPRD, General Practice Research Database; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist; OPCRD, Optimum Patient Care Research Database; Rx, therapy; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.
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Small- versus large-particle inhaled corticosteroid in COPD
Respiratory patients
in the GPRD and OPCRD
n=1,515,507

Inclusion criteria
Patients on ICS at any time post-1990
± ipratropium/salbutamol
± long-acting anticholinergic
± theophylline

Excluded
Patients not on any ICS therapy
(n=819,018)
Patients prescribed
any ICS inhalers
n=696,489

Excluded
-No further ICS therapy (n=114,045)
-No increase in ICS dose ever (n=383,753)
-Started on DPI, BAI, budesonide, or ciclesonide
or first increase via DPI or BAI (n=81,480)
-No recorded COPD diagnosis (n=93,249)
-Started on ICS before 1997 (n=8,708)
-Started ICS at age <40 years (n=328)
-Other chronic respiratory disease (n=254)
-Prescribed an FDC ICS-LABA in baseline
(n=163)
-Multiple ICS in baseline year (n=137)
-Not registered at practice for 1 year before and
2 years after index date (n=5,089)

Patients prescribed
beclomethasone or fluticasone
n=9,283
Excluded
-<2 COPD Rx baseline year (n=1,693)
-Multiple ICS or FDC prescribed at index
date (n=298)
-Duplicated in GPRD and OPCRD (n=830)
-FEV1/FVC ratio >0.7 (n=656)
-On large-particle beclomethasone (n=3,909)
Matching criteria applied
-Same sex
-Age ±5 years
-Baseline year no COPD
exacerbations (0, 1, ≥2)
-Baseline Rx: (a) SABA/SAMA/
SABA + SAMA, (b) LABA,
(c) LAMA, (d) LABA + LAMA ±
SABA ± SAMA, or (e) other

Patients with COPD initiating
ICS therapy as
Extrafine beclomethasone n=629
Fluticasone n=1,268

Randomize matching patients 1:1*
*Software used to randomly pick
unique matched patients

-Year of index date ±1 years
-Baseline year mean ICS dose
(0–250, 251–500, >500 µg/d)
1:1 uniquely matched pairs: n=252

Lost on matching
Extrafine beclomethasone n=306
Fluticasone n=895
Double matches lost on
randomisation 1:1
Extrafine beclomethasone n=54
Fluticasone n=643
Excluded pairs:
-COPD not confirmed by spirometry
(n=52)

Total matched patients included
Extrafine beclomethasone n=189
Fluticasone n=189

-Non-smokers (n=6)
-Asthma diagnosis at <40 years old
(n=5)

Figure S2 Patient selection and matching for the step-up sample.
Abbreviations: BAI, breath-actuated inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; GPRD, General Practice Research Database; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting
muscarinic antagonist; OPCRD, Optimum Patient Care Research Database; Rx, therapy; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist.
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Figure S3 Time plots of the COPD diagnosis showing (A) the time of the COPD
diagnosis relative to time of first asthma diagnosis for the full unmatched population
who also had a recorded asthma diagnosis, and (B) the time of the COPD
confirmation (by FEV1/FVC ratio ,0.7) relative to time of the asthma diagnosis for
these patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; dx, diagnosis;
SD, standard deviation; FEV1, forced expiratory volume in 1 second; FVC, forced
vital capacity.
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